Multicentric , randomized controlled trial performed in Europe in which ACE inhibitor (benazepril 0.2 mg/kg/d) versus placebo were tested in 66 patients with IgA nephropathy between age group of 9 – 35 years of age with proteinuria (1-3.5 g/d/proteinuria) and CrCl > 50 ml/min. Primary outcome was progression of kidney disease (>30% decrease of CrCl). Secondary outcomes were composite outcomes of > 30 percent decrease in creatinine clearance or worsening of proteinuria > 3.5 g/day. The other secondary outcome was partial (< 0.5 gm / day ) or complete remission of proteinuria (< 160mg / day ). Progression of renal failure tends to be slower in ACE inhibitors although not statistically significant with respect to the primary end point . Treatment with ACE inhibitor was an independent predictor of good prognosis and survival to the combined secondary end point.
